论文部分内容阅读
目的探讨门冬胰岛素30(诺和锐30)和预混精蛋白生物合成人胰岛素30R(诺和灵30R)对斋月期间2型糖尿病患者血糖控制的临床疗效及安全性。方法选取自2014年3月-2015年9月我院门诊收治的60例2型糖尿病患者作为研究对象,采取数字抽签法进行1∶1随机分为对照组和实验组。所有患者均给予二甲双胍治疗,对照组患者在二甲双胍基础上加用精蛋白生物合成人胰岛素30R(诺和灵30R)治疗,实验组患者在二甲双胍基础上加用门冬胰岛素30(诺和锐30)治疗。对比斋月前、后患者的空腹血糖(FBG)、餐后血糖(2hp G)、糖化血红蛋白(Hb AIC)、总胆固醇(TC)、甘油三酯(TG)的变化,并对比低血糖事件发生情况。结果斋月前两组患者的FBG、2h PG、Hb AIC、TC、TG水平差异均无统计学意义(P>0.05);斋月后实验组患者的FBG、2h PG、Hb Al C、TC、TG水平均低于对照组(P<0.05)。实验组斋月期间的低血糖事件发生率(20%)明显低于对照组(53%)(P<0.05)。结论在斋月期间给予2型糖尿病患者诺和锐30治疗较诺和灵30R能更有效地控制患者的血糖,同时降低低血糖事件的发生风险。
Objective To investigate the clinical effects and safety of insulin aspart 30 (Novo-Rui-30) and pre-mixed protamine biosynthesis human insulin 30R (Novo-Regen 30R) on glycemic control in type 2 diabetic patients during Ramadan. Methods Sixty patients with type 2 diabetes mellitus admitted to our hospital from March 2014 to September 2015 were selected and randomly divided into control group and experimental group by digital lottery method. All patients were treated with metformin. Patients in the control group were treated with protamine biosynthesis of human insulin 30R (Novolin 30R) on the basis of metformin. Patients in the experimental group were given insulin aspart 30 (Novo-Rui 30) on the basis of metformin, treatment. The changes of fasting blood glucose (FBG), postprandial blood glucose (2hp G), Hb AIC, total cholesterol (TC) and triglyceride (TG) in patients before and after Ramadan were compared and the incidence of hypoglycaemia . Results There were no significant differences in FBG, 2h PG, Hb AIC, TC and TG levels between the two groups before Ramadan (P> 0.05). After Ramadan, FBG, 2h PG, Hb Al C, TC and TG levels Were lower than the control group (P <0.05). The incidence of hypoglycaemia during the Ramadan in the experimental group (20%) was significantly lower than that in the control group (53%) (P <0.05). Conclusion Novo-type 30 treatment of type 2 diabetics during the holy month of Ramadan may be more effective in controlling the patient’s blood glucose and at the same time reduce the risk of hypoglycaemic events than norepinephri 30R.